Skip to main content
    J

    Jasper Therapeutics Inc (JSPR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.53
    +0.03 (+6.21%)

    Market Cap: $16.49M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(13/20)
    Avg Surprise
    -1.64%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.56
    Range$-0.56 - $-0.56
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.560.0%
    60d ago$-0.560.0%
    30d ago$-0.560.0%
    7d ago$-0.560.0%
    Current$-0.56
    Revenue Consensus
    $2M
    Range$0 - $12M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.87
    Range$-0.87 - $-0.87
    1 analysts
    Revenue Consensus
    $10M
    Range$10M - $10M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.87---
    Sep 26EST
    		-$-0.56---
    Jun 26
    Reported Aug 13
    		$-0.24$-0.37+35.14%Beat+86.2%
    Mar 26
    Reported May 14
    		$-0.38$-0.54+29.63%Beat+73.0%
    Dec 25
    Reported Mar 30
    		$-0.54$-0.82+33.82%Beat+66.6%
    Sep 25
    Reported Nov 10
    		$-1.13$-1.21+6.61%Beat+8.9%
    Jun 25
    Reported Aug 13
    		$-1.74$-1.33-30.83%Miss-79.4%
    Mar 25
    Reported May 12
    		$-1.41$-1.48+4.50%Beat-36.9%
    Dec 24
    Reported Feb 27
    		$-1.62$-1.23-31.71%Miss-8.0%
    Sep 24
    Reported Nov 7
    		$-1.24$-1.08-14.81%Miss+23.9%
    Jun 24
    Reported Aug 13
    		$-0.97$-1.12+13.39%Beat+35.8%
    Mar 24
    Reported May 14
    		$-1.03$-1.23+16.26%Beat+29.9%
    Dec 23
    Reported Mar 4
    		$-1.50$-1.57+4.46%Beat-316.7%
    Sep 23
    Reported Nov 9
    		$-1.63$-1.50-8.67%Miss+49.1%
    Jun 23
    Reported Aug 11
    		$-1.51$-1.47-2.72%Miss+38.4%
    Mar 23
    Reported May 12
    		$-1.47$-1.50+2.00%Beat+58.5%
    Dec 22
    Reported Mar 8
    		$-0.36$-0.36+0.00%Beat+54.4%
    Sep 22
    Reported Nov 10
    		$-3.20$-3.70+13.51%Beat-19.9%
    Jun 22
    Reported Aug 12
    		$-2.45$-3.60+31.94%Beat-87.0%
    Mar 22
    Reported May 12
    		$-3.54$-3.40-4.12%Miss-904.5%
    Dec 21
    Reported Mar 18
    		$-0.79$-0.34-132.35%Miss-7800.0%
    Sep 21
    Reported Nov 12
    		$-2.67$-2.70+1.11%Beat-13250.0%
    Jun 21
    Reported Aug 16
    		$-1.31N/AN/ABeat-6450.0%
    Mar 21
    Reported May 24
    		$0.44N/AN/ABeat+300.0%
    Dec 20
    Reported Mar 30
    		$-0.01N/AN/ABeat-
    Sep 20
    Reported Nov 10
    		$-0.02N/AN/ABeat-19900.0%
    Jun 20
    Reported Aug 13
    		$-0.02N/AN/ABeat-
    Mar 20
    Reported May 13
    		$0.11N/AN/ABeat-
    Dec 19
    Reported Mar 26
    		$0.00$0.00N/ABeat-
    Sep 19
    Reported Nov 20
    		$-0.00N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.23EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-255.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio1.47xQuick Ratio1.47x
    Trading Statistics
    Beta3.04Avg Volume385.32K
    52-Week High$2.6952-Week Low$0.32

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.55
    SMA 20$0.58
    SMA 50$0.66
    SMA 200$0.92
    EMA 10$0.55
    EMA 20$0.57
    EMA 50$0.62
    EMA 200$1.06

    MACD

    Line: -0.04Signal: -0.03Hist: -0.00

    ADX

    ADX: 14.6+DI: 13.3-DI: 21.4

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$0.63

    Bollinger Bands

    Upper Band$0.65
    Lower Band$0.50
    %B Position2604%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    40.8

    Momentum Oscillators

    Stoch %K17.5
    Stoch %D12.9
    Williams %R-66.5
    ROC (10d)-11.0%
    Momentum-0.07
    CCI (20d)-134.4
    MFI (14d)38.7

    Volatility Measures

    ATR (14d)$0.06(11.0%)
    StdDev (20d)0.04
    Hist Vol76.9%(High)

    Volume Flow

    VWAP$0.52
    OBV-40.1M
    AD Line-49.0M
    CMF (20d)-0.105

    Volume Metrics

    Avg Vol (20d)383.4K
    Vol Ratio1.0x
    VWMA (20d)$0.57

    Pivot Points

    R3$0.58
    R2$0.55
    R1$0.53
    Pivot Point$0.49
    S1$0.47
    S2$0.44
    S3$0.41

    Advanced Oscillators

    TSI-20.34
    Ultimate Osc49.0
    KST-167.16

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.17M$0$0$0$2.05M$0
    Cost of Revenue$0$0$290,000$0$0$0$587,000$0$0$0$82,000$0
    Gross Profit$0$0$-290,000$0$0$0$587,000$0$0$0$-82,000$0
    Operating Expenses$9.21M$10.95M$15.84M$19.17M$27.08M$21.80M$25.29M$19.89M$15.99M$15.07M$17.73M$19.36M
    R&D$5.13M$5.81M$11.36M$14.39M$21.20M$16.16M$19.77M$14.46M$11.30M$10.30M$13.84M$14.85M
    SG&A$4.07M$5.14M$4.48M$4.78M$5.88M$5.64M$5.51M$5.43M$4.70M$4.77M$3.89M$4.51M
    Operating Income$-9,207,000$-10,952,000$-15,839,000$-19,166,000$-27,076,000$-21,802,000$-25,285,000$-19,889,000$-15,993,000$-15,072,000$-17,725,000$-19,362,000
    Interest Income$82,000$164,000$338,000$342,000$437,000$624,000$938,000$1.28M$1.45M$1.39M$1.23M$1.43M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-2,760,000$-1,174,000$-9,101,000$-18,736,000$-26,723,000$-21,241,000$-24,321,000$-18,637,000$-14,583,000$-13,728,000$-16,581,000$-17,544,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,760,000$-1,174,000$-9,101,000$-18,736,000$-26,723,000$-21,241,000$-24,321,000$-18,637,000$-14,583,000$-13,728,000$-16,581,000$-17,544,000
    EBITDA$-2,821,000$-1,317,000$-9,149,000$-18,849,000$-26,902,000$-21,586,000$-25,014,000$-19,380,000$-15,734,000$-14,826,000$-17,532,000$-18,701,000
    EBIT$-2,842,000$-1,338,000$-9,439,000$-19,078,000$-27,160,000$-21,865,000$-25,259,000$-19,921,000$-16,033,000$-15,114,000$-17,815,000$-18,977,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about JSPR

    News

    Jasper Therapeutics Completes IgA Nephropathy Enrollment for KP104 Phase 2 Study

    Jasper Therapeutics has completed enrollment for the IgA nephropathy cohort of its Phase 2 renal basket study for vensobafusp alfa (KP104) and anticipates releasing initial interim data by the end of 2026. KP104 is...

    The Clinical Trial Vanguard•10/16/26•Bullish

    Jasper completes 18-patient study. Jasper Therapeutics stock is valued at USD 17.7 million

    Jasper Therapeutics completed enrollment of 18 patients in a Phase 2 kidney study for IgA nephropathy on October 15, 2026, with initial interim data expected by year-end 2026. The company's stock, JSPR...

    ad-hoc-news.de•10/15/26•Somewhat-Bearish

    Jasper completes 18-patient study. Jasper Therapeutics stock is valued at USD 17.7 million

    Jasper Therapeutics completed enrollment of 18 patients in a Phase 2 kidney study, with its stock valued at USD 17.7 million. The company expects interim data by year-end 2026 and plans further clinical development....

    ad-hoc-news.de•10/15/26•Somewhat-Bullish

    Jasper Therapeutics completes IgAN cohort enrollment; interim data due by year-end 2026

    Jasper Therapeutics has completed enrollment for the IgA nephropathy cohort in its Phase 2 vensobafusp alfa basket study and anticipates initial interim data by year-end 2026. The study includes 18 patients across three...

    TradingView•10/15/26•Somewhat-Bullish

    William Blair Upgrades Jasper Therapeutics(JSPR.US) to Buy Rating

    William Blair has upgraded Jasper Therapeutics (JSPR.US) stock to a Buy rating. This upgrade suggests a positive outlook from the investment firm regarding the company's future performance.

    Moomoo•10/15/26•Bullish

    JSPR Valuation and Fair Value

    P/E
    -0.2x
    P/B
    10.8x
    See GNG's fair value

    JSPR Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -255.0%

    JSPR Competitors

    CompanyTicker
    Quantum BioPharma Ltd.QNTM
    Dyadic International IncDYAI
    Neuphoria Therapeutics IncNEUP
    Concord Medical Services HoldingsCCM
    ReWalk Robotics LtdLFWD
    Psyence Biomedical Ltd. Common SharesPBM
    Retractable Technologies IncRVP
    Cyclerion Therapeutics IncCYCN

    Sector: Healthcare

    JSPR Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    4.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.56
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About JSPR

    Does JSPR pay dividends?

    Jasper Therapeutics Inc (JSPR) does not currently pay a regular dividend.

    What is JSPR's market cap?

    Jasper Therapeutics Inc (JSPR) has a market capitalization of $16.49M with a current stock price of $0.53.

    Related stocks

    Sector: Healthcare

    All stocks starting with J

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In